Should all diabetic patients receive aspirin? Results from recent trials

British Journal of Cardiology

Volumn 12, Issue 4, 2005, Pages 275-282

  Barwell, Nick ^a   Marshall, Gillian ^a   McDougall, Claire ^a   Brady, Adrian J B ^a   Fisher, Miles ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antiplatelet therapy; Aspirin; Cardiovascular disease; Diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; OMEGA 3 FATTY ACID; PLACEBO;

ARTICLE; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DATA ANALYSIS; DIABETES MELLITUS; DRUG USE; HUMAN; HYPERTENSION; META ANALYSIS; MORTALITY; POPULATION; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; VASCULAR DISEASE;

EID: 23144460480     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
2. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: prinicipal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324:71-86.
4. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268:1292-301.
5. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296:313-16.
6. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-35.
7. Ridker PM, Cook NR, Lee I-M et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
8. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357:89-95.
9. Sacco M, Pellegrini F, Roncaglioni MC et al. on behalf of the PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 2003;26:3264-72.
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
11. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-8.
12. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment Elevation. N Engl J Med 2001;345:494-502.
13. Mehta SR, Yusuf S, Peters RJG et al. for the Clopidogrel in Unstable Angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous intervention: the PCI-CURE study. Lancet 2001;358:527-33.
14. Sabatine MS, Cannon CP, Gibson CM for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352:1179-89.
15. Diener H-C, Bogousslavsky J, Brass LM et al. on behalf of the MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 2004;364:331-7.
16. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycaemia a late manifestation? The role of NOS, NO and redox stress. Cardiovasc Diabetol 2003; 2:2.
17. Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64.
18. Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003;92:1362-5.
19. Nystrom T, Nygren A, Sjoholm A. Persistent endothelial dysfunction is related to elevated CRP levels in type 2 diabetic patients after acute myocardial infarction. Clin Sci 2005;108:121-8.
20. Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 2002;105:1620-2.